Cargando…

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4

Numerous research reports have witnessed dramatic advancements in cancer therapeutic approaches through immunotherapy. Blocking immunological checkpoint pathways (mechanisms employed by malignant cells to disguise themselves as normal human body components) has emerged as a viable strategy for devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Pratibha, Khan, Fahad, Qari, Huda A., Upadhyay, Tarun Kumar, Alkhateeb, Abdulhameed F., Oves, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952773/
https://www.ncbi.nlm.nih.gov/pubmed/35337133
http://dx.doi.org/10.3390/ph15030335
_version_ 1784675700200964096
author Pandey, Pratibha
Khan, Fahad
Qari, Huda A.
Upadhyay, Tarun Kumar
Alkhateeb, Abdulhameed F.
Oves, Mohammad
author_facet Pandey, Pratibha
Khan, Fahad
Qari, Huda A.
Upadhyay, Tarun Kumar
Alkhateeb, Abdulhameed F.
Oves, Mohammad
author_sort Pandey, Pratibha
collection PubMed
description Numerous research reports have witnessed dramatic advancements in cancer therapeutic approaches through immunotherapy. Blocking immunological checkpoint pathways (mechanisms employed by malignant cells to disguise themselves as normal human body components) has emerged as a viable strategy for developing anticancer immunity. Through the development of effective immune checkpoint inhibitors (ICIs) in multiple carcinomas, advances in cancer immunity have expedited a major breakthrough in cancer therapy. Blocking a variety of ICIs, such as PD-1 (programmed cell death-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has improved the immune system’s efficacy in combating cancer cells. Recent studies also supported the fact that ICIs combined with other potent antitumor candidates, such as angiogenic agents, could be a solid promising chemopreventive therapeutic approach in improving the effectiveness of immune checkpoint inhibitors. Immune checkpoint blockade has aided antiangiogenesis by lowering vascular endothelial growth factor expression and alleviating hypoxia. Our review summarized recent advances and clinical improvements in immune checkpoint blocking tactics, including combinatorial treatment of immunogenic cell death (ICD) inducers with ICIs, which may aid future researchers in creating more effective cancer-fighting strategies.
format Online
Article
Text
id pubmed-8952773
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89527732022-03-26 Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4 Pandey, Pratibha Khan, Fahad Qari, Huda A. Upadhyay, Tarun Kumar Alkhateeb, Abdulhameed F. Oves, Mohammad Pharmaceuticals (Basel) Review Numerous research reports have witnessed dramatic advancements in cancer therapeutic approaches through immunotherapy. Blocking immunological checkpoint pathways (mechanisms employed by malignant cells to disguise themselves as normal human body components) has emerged as a viable strategy for developing anticancer immunity. Through the development of effective immune checkpoint inhibitors (ICIs) in multiple carcinomas, advances in cancer immunity have expedited a major breakthrough in cancer therapy. Blocking a variety of ICIs, such as PD-1 (programmed cell death-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has improved the immune system’s efficacy in combating cancer cells. Recent studies also supported the fact that ICIs combined with other potent antitumor candidates, such as angiogenic agents, could be a solid promising chemopreventive therapeutic approach in improving the effectiveness of immune checkpoint inhibitors. Immune checkpoint blockade has aided antiangiogenesis by lowering vascular endothelial growth factor expression and alleviating hypoxia. Our review summarized recent advances and clinical improvements in immune checkpoint blocking tactics, including combinatorial treatment of immunogenic cell death (ICD) inducers with ICIs, which may aid future researchers in creating more effective cancer-fighting strategies. MDPI 2022-03-09 /pmc/articles/PMC8952773/ /pubmed/35337133 http://dx.doi.org/10.3390/ph15030335 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pandey, Pratibha
Khan, Fahad
Qari, Huda A.
Upadhyay, Tarun Kumar
Alkhateeb, Abdulhameed F.
Oves, Mohammad
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
title Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
title_full Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
title_fullStr Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
title_full_unstemmed Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
title_short Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
title_sort revolutionization in cancer therapeutics via targeting major immune checkpoints pd-1, pd-l1 and ctla-4
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952773/
https://www.ncbi.nlm.nih.gov/pubmed/35337133
http://dx.doi.org/10.3390/ph15030335
work_keys_str_mv AT pandeypratibha revolutionizationincancertherapeuticsviatargetingmajorimmunecheckpointspd1pdl1andctla4
AT khanfahad revolutionizationincancertherapeuticsviatargetingmajorimmunecheckpointspd1pdl1andctla4
AT qarihudaa revolutionizationincancertherapeuticsviatargetingmajorimmunecheckpointspd1pdl1andctla4
AT upadhyaytarunkumar revolutionizationincancertherapeuticsviatargetingmajorimmunecheckpointspd1pdl1andctla4
AT alkhateebabdulhameedf revolutionizationincancertherapeuticsviatargetingmajorimmunecheckpointspd1pdl1andctla4
AT ovesmohammad revolutionizationincancertherapeuticsviatargetingmajorimmunecheckpointspd1pdl1andctla4